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Abstract
Background: The rate of transcription of the HIV-1 viral genome is mediated by the interaction
of the viral protein Tat with the LTR and other transcriptional machinery. These specific
interactions can be affected by the state of post-translational modifications on Tat. Previously, we
have shown that Tat can be phosphorylated and acetylated in vivo resulting in an increase in the rate
of transcription. In the present study, we investigated whether Tat could be methylated on lysine
residues, specifically on lysine 50 and 51, and whether this modification resulted in a decrease of
viral transcription from the LTR.
Results: We analyzed the association of Tat with histone methyltransferases of the SUV39-family
of SET domain containing proteins in vitro. Tat was found to associate with both SETDB1 and
SETDB2, two enzymes which exhibit methyltransferase activity. siRNA against SETDB1 transfected
into cell systems with both transient and integrated LTR reporter genes resulted in an increase in
transcription of the HIV-LTR in the presence of suboptimal levels of Tat. In vitro methylation assays
with Tat peptides containing point mutations at lysines 50 and 51 showed an increased
incorporation of methyl groups on lysine 51, however, both residues indicated susceptibility for
methylation.
Conclusion: The association of Tat with histone methyltransferases and the ability for Tat to be
methylated suggests an interesting mechanism of transcriptional regulation through the
recruitment of chromatin remodeling proteins to the HIV-1 promoter.
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Background
The HIV-1 genome incorporates nine viral genes, all of
which are expressed from a single promoter located
within the viral long terminal repeat (LTR) [1,2]. The
activity of the HIV-1 promoter is strongly dependant on
the viral transactivator, Tat, the protein responsible for
transcriptional activation and elongation [3-8]. The main
function of Tat is to activate the HIV-1 LTR by binding to
an RNA stem-loop structure, TAR [3,4,6,9-11]. This inter-
action initiates a binding cascade where cellular transcrip-
tion factors such as Cdk9 and cyclin T1 are recruited to the
HIV-1 promoter to facilitate viral transcription [12-15].
Tat mediates the functional modifications associated with
viral transcription primarily by interacting with host cellu-
lar kinases, specifically to phosphorylate the large subunit
of RNA Pol II CTD resulting in the activation of elonga-
tion [12,16,17]. In addition to the recruitment of host cel-
lular proteins and enzymes for transcriptional initiation,
such as NF-κB, Sp1, and TFIID, Tat has also been shown
to bind a number of other factors which regulate chroma-
tin structure located at the HIV promoter thus allowing
access to the LTR DNA [9,10,18-27].
The basic building blocks of chromatin are organized into
nucleosomes, each of which is made up of 146 bp of DNA
wrapped around an octamer of histone proteins that con-
sists of two copies of each of H2A, H2B, H3, and H4. The
nucleosome can be divided into two domains, one of
which is the structured histone-DNA and histone-histone
globular domain, and the other is the highly basic N-ter-
minal histone tails which contain multiple sites for post-
translational modifications including acetylation, phos-
phorylation, methylation, ubiquitination, and sumoyla-
tion [28-31]. The post-translational modifications present
on each histone tail can direct higher order chromatin
structure and consequently, transcription through a cycle
of conflicting activation and repression signals [32-34].
Histone acetyltransferases (HATs), histone deacetylases
(HDACs), kinases, and histone methyltransferases
(HMTs) are all responsible for the addition/removal of
covalent modifications on the histone tails [35-37]. In the
case of retroviruses, the integration of proviral DNA into
the genome of an infected cell requires the manipulation
of cellular transcriptional machinery as well as cellular
chromatin remodelers to accomplish proliferation, repli-
cation, and latent infection of the virus. Transcriptional
silencing of the HIV-1 genome may be directly correlated
with the state of chromatin packaging near the viral inte-
gration site [38-40].
Histone methyltransferases (HMTs) can methylate
arginine residues such as 2, 8, 17, and 26 on H3 and resi-
due 3 on H4. HMTs can also methylate specific lysine res-
idues such as 4, 9, 27, 36, and 79 on H3 and residue 20 on
H4 which serve as markers for the recruitment of chroma-
tin organization complexes [41-43]. Specifically, lysine
methylation is catalyzed by the SET-domain family of pro-
teins which function to transfer a methyl group from S-
adenosyl-L-methionine to the amino group of the lysine
side chain, often on lysine 9 of H3 (H3-K9) [41]. Histori-
cally, the methylation of H3-K9 has been linked to func-
tionally repressed chromatin [33,44,45]. The selective
methylation of H3-K9 results in the recruitment of the
HP1 family of heterochromatic binding proteins therefore
distinguishing transcriptionally silent chromatin regions
[28,33,35,44,46-49]. The SET domain is comprised of
approximately 130 amino acids surrounded by other
domains which confer substrate specificity. The SUV39
family of SET-domain containing proteins, SUV39H1,
SUV39H2, G9a, EHMT1, SETDB1, SETDB2, and SETMAR,
specifically methylate lysines on Histone H3, however,
more recent studies have also shown a preference for
other proteins in addition to histones, therefore lending
this family the name of protein lysine methyltransferases
[41,50,51].
Lysine is a ~129 Da basic amino acid which is subject to
multiple post-translational modifications such as acetyla-
tion, methylation, ubiquitination, and sumoylation.
Lysine residues contain an ε-amino group which is highly
catalytic for many metabolic and chemical reactions. Spe-
cifically, lysine residues can be mono-, di-, or trimethyl-
ated, each of which can differentially regulate chromatin
structure and transcription. The chemical structure of
lysine allows for only one type of post-translational mod-
ification to be present at any time, also allowing for steric
hindrance of the modifications. This system of modifica-
tion results in the need for both methylases and demeth-
ylases in response to particular cellular events. Of
particular interest, while a lysine contains a methyl group,
it cannot be simultaneously acetylated, therefore resulting
in either an "on" or "off" orientation of the molecule. This
consequence of the addition of a modification is impor-
tant when regulating transcriptional activation or repres-
sion.
Tat itself is also subject to various post-translational mod-
ifications by host cellular proteins. Tat is phosphorylated,
acetylated at lysines 28, 50, and 51, ubiquitinated at lysine
71, and methylated at arginine residues 52 and 53 [52-
54]. Specifically, the basic domain (residues 49–57),
which confers TAR RNA binding, is highly conserved and
subject to acetylation on residues K28, K50, and K51 by
CBP/p300, the result of which is crucial for Tat transacti-
vation [55-59]. The acetylation of these residues is of great
interest as a target for inhibition therapies; the prevention
of acetylation would ensure only a low level of viral DNA
is transcribed. Also, Tat retains its ability to dynamically
shape the foundation of viral transcription through host
machinery via its involvement with host cellular kinases.Retrovirology 2008, 5:40 http://www.retrovirology.com/content/5/1/40
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Recent studies have shown that Tat can be methylated by
protein arginine methyltransferases (PRMTs) on arginine
residues 52 and 53, resulting in a decreased interaction
with TAR and cyclin T1 complex formation, therefore
decreasing HIV-1 transcriptional activation [54,60]. Here
we investigated the methylation of lysine residues 50 and
51, which would compete with and therefore prevent the
acetylation of the same residues and any subsequent viral
transactivation. We especially were interested in these
lines of investigation, since we had previously observed
the presence of TIF-1α (a DNA-binding chromatin remod-
eling protein) when using proteomic analysis to identify
cellular proteins bound to unmodified Tat [31]. Here, we
report the specific methylation of Tat lysine residues 50
and 51 by protein lysine methyltransferases. Initial screen-
ings of the members of the SET-family for specific interac-
tions with Tat in vitro revealed SETDB1/2 to be substrate
specific for Tat. We observed that the H3-K9 methyltrans-
ferase SETDB1 can specifically methylate Tat preferen-
tially at lysine 51. SiRNA knockdown studies of SETDB1
in transient transfected cells or cells with an integrated
LTR reporter gene and associated cellular factors indicated
an increase in LTR transactivation in the absence of the
inhibitory modification. Collectively, our results imply
that the modification of Tat at lysine 51 may contribute to
an "on" or "off" phenotype of the HIV-1 promoter.
Results
Lysine residue methylation of Tat by histone 
methyltransferases
The core histone tails have long been a primary example
of the importance of post-translational modifications in
transcriptional activation and repression. Histone modifi-
cations control the higher order chromatin structure and
are facilitated by enzymes such as HATs, HDACs, and
HMTs. Various combinations of modifications can be
involved in the recruitment of specific transcription fac-
tors, therefore suggesting the "histone code" hypothesis.
Many specific residues of the core histone tails have been
identified as integral to transcriptional activation and
repression and, consequently, their modifications have
been documented. For instance, integral residues such as
H3K9, H3K18, and H3K27 can be both acetylated and
methylated, however, not simultaneously. Lysine methyl-
ation of histones is carried out by the SET-domain con-
taining enzymes; therefore, this family of proteins was
subjected to further investigation in the current manu-
script.
Tat associates with SETDB1 and SETDB2 in vitro
The SUV39 family of SET-domain containing proteins,
SUV39H1, SUV39H2, G9a, EHMT1, SETDB1, SETDB2
(unpublished data), and SETMAR, specifically methylate
lysine residues of Histone H3, but have also recently been
referred to as general protein lysine methyltransferases.
We investigated the association of Tat with these enzymes
in vitro. EHMT1 was excluded from our studies as it is a
Drosophila analog. SUV39H2 was investigated; however
no consistant positive results were seen across immuno-
precipitations (undetermined, data not shown). We
pulled down protein complexes bound to purified forms
of Tat peptides and performed Western blots against each
of the above methyltransferases. Purified wild type Tat
peptides linked to Biotin was found to associate with
SETDB1, SETDB2, and SUV39H1 when using whole cell
extracts (Figure 1A, Lane 3). An acetylated Tat peptide
(lysine residues 50, 51) linked to Biotin was used as a test
for specificity of the enzyme binding in vitro (Figure 1A,
Lane 4). SUV39H1 was present in the complex with the
unmodified and the acetylated Tat peptides; however
SETDB1 and SETDB2 exhibited specificity for only the
unmodified Tat peptide. Figure 1B utilized the same pull-
down complexes with Biotin-labeled wild type and
acetylated Tat and probed for the presence of G9a and
SETMAR. Both methyltransferases were found to associate
with the wild type and acetylated forms of Tat (although
less binding with SETMAR), therefore not conferring spe-
cificity for the modifications tested (Lanes 2 and 3). We
then asked if the binding of SETDB1 to wild type Tat was
specific using Westerns for BRG1 as well as performing Tat
peptide and protein competitions. We have previously
shown that acetylated Tat has a high affinity for bromodo-
main-containing complexes including members of the
SWI/SNF family [61,62]. Results in panel C show that
acetylated Tat, but not unmodified Tat, bound to BRG1.
We next performed peptide competition assays with the
Tat 42–51 peptide (1:10 ratio) as well as using purified Tat
1–86 (1:10 ratio) and found a complete competition
when assaying for the presence of SETDB1.
As SETDB1 and SETDB2 were found to bind the unmodi-
fied Tat peptide, we next looked at the interaction with the
full length wild type Tat protein. GST-bound Tat and Tax
(control) proteins were allowed to incubate with whole
cell extracts, and the associated complexes were probed
for the presence of SETDB1 and SETDB2. SETDB1 was
shown to associate with the full length Tat protein in
greater abundance than SETDB2 (Figure 1D, Lane 3). The
results of panels A-D are summarized in Figure 1E. Here,
each enzyme utilized in our in vitro binding assay is
depicted for their Tat binding affinity indicated on the
right-hand side. SETDB1 and SETDB2 have the greatest
affinity for wild type Tat, whereas, SUV39H1, SUV39H2,
G9a, and SETMAR all bound to both unmodified and
acetylated Tat to varying degrees. As SETDB1 had the high-
est affinity over SETDB2, this enzyme became the focus of
further experimentation.Retrovirology 2008, 5:40 http://www.retrovirology.com/content/5/1/40
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SETDB1 knockdown increases the transactivation of the 
viral LTR
Results above indicated that SETDB1 may be a potential
candidate for the methylation of Tat. Next, we performed
two tandem experiments; one which utilized a transient
transfection of the LTR-CAT reporter system and one that
utilized an integrated LTR-Luc reporter system. We per-
formed a LTR CAT transfection experiment with increas-
ing amounts of Tat and various fixed concentrations of
siRNAs against SETDB1 and other related enzymes. We
also used siGFP and siCDK4 as two negative controls in
the transfection. Results in Figure 2A indicate that LTR
activity is low at 3 ug concentration in CEM cells (panel A,
lane 1) while increasing concentrations of Tat increased
the activated transcription (0.01, 0.1, 1.0 ug; lanes 2 – 4).
The LTR activity was maximal in the presence of 1.0 ug of
Tat in these assays. We then asked if siRNAs against vari-
ous methyltransferases could indeed activate the LTR in
the presence of suboptimal concentrations of Tat. Results
of such an experiment are shown in Figure 2A lanes 5 –
10. All of these lanes were transfected with LTR CAT at 1.0
ug and Tat at 0.1 ug per transfection. This low concentra-
tion of Tat normally does not optimally activate LTR tran-
scription in these cells as seen in lane 3. Results of siRNA
transfections indicate that suppression of SETDB1 and
TIF-1 show the maximal amount of activity, followed by
G9A and HP1. Surprisingly, the two controls, i.e. siGFP
and siCDK4, also showed somewhat of an increase tran-
scriptional activity, thereby serving as negative controls
for siRNA transfection. None of these siRNAs activated the
basal transcription of LTR (data not shown). All four siR-
NAs against SETDB1, TIF, G9A, and HP1 decreased the
endogenous protein levels by more than 80% (the bottom
of panel A).
We next performed a similar set of experiments in an LTR
integrated system. TZM-bl cells are HeLa cells which con-
tain both an integrated LTR-Luc reporter gene and an inte-
The co-precipitation of Tat with SET-domain containing proteins Figure 1
The co-precipitation of Tat with SET-domain containing proteins. A) Biotin-labeled wild type Tat (Lane 3) and 
acetylated (residues 50 and 51) Tat (Lane 4) peptide immunoprecipitated complexes were probed for the presence of SETDB1, 
SETDB2, and SUV39H1. 1/20 of input was used as positive control for western blots. B) Biotin-labeled wild type Tat (Lane 2) 
and acetylated Tat (Lane 3) peptide complexes were probed for the presence of bound G9a and SETMAR. C) Positive control 
reaction using BRG1 pulldown for the acetylated Tat [61], and competition experiment with Tat 42–51 peptide (1:10 ratio) as 
well as purified wild type Tat 1–86 (1:10 ratio) to compete out SETDB1 binding. D) GST-bound wild type Tat and wild type 
Tax protein complexes were probed for the presence of bound SETDB1 and SETDB2. E) A summary of the Tat binding inter-
actions between all members of the SUV39 family as predicted by SMART) [73]. Under both the Unmodified Tat and 
Acetylated Tat binding affinity column, a "-" indicates that the enzyme does not bind to the indicated form of Tat, while increas-
ing amounts of "+" indicates that the enzyme bound to the indicated form of Tat with a greater specificity. The "UN" indicates 
that binding affinities were undetermined.Retrovirology 2008, 5:40 http://www.retrovirology.com/content/5/1/40
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grated LTR-β-Gal gene. To initiate viral transactivation, Tat
must be transfected into these cells. We plated cells and
allowed them to grow overnight before transfecting both
Tat and the relevant siRNAs. We initially titrated Tat at
0.01, 0.1, and 1.0 ug to ensure that we could obtain an
accurate standard curve for the luciferase readings (data
not shown). Next, we transfected Tat into the cells at 0.1
ug, a suboptimal level, so that we could detect subtle dif-
ferences in transcription activity resulting from the siRNA
knockdowns. siGFP, siSETDB1, siTIF-1, and siG9a were all
transfected along with Tat and 48 hours later cells were
harvested for a luciferase assay. Figure 2B shows the
results of the luciferase assay with the each value normal-
ized to the siGFP control and activation represented in rel-
ative luciferase units. The knockdown of SETDB1 in these
cells resulted in ~12 fold increase in activation as com-
pared to the Tat control alone (lane 2). The knockdown of
the other two proteins resulted in about ~6 fold increase
in activation as compared to the Tat control. A confirma-
tion western blot of the knockdown of SETDB1 and other
proteins are shown on the bottom of panel B. Collectively,
these results imply that reduced SETDB1 levels in a cell
results in greater activation of the LTR.
Methylation of Tat at Lysines 50 and 51 by SETDB1 and 
their functional significance
Next, we asked which lysine residues could specifically be
methylated by SETDB1. We utilized an in vitro methyl-
transferase assay incorporating a reaction mixture con-
taining substrate, enzyme, buffer, and S-Adenosyl-L-
Transiently transfected and integrated LTR reporter systems exhibit increased transactivation in the absence of SETDB1 Figure 2
Transiently transfected and integrated LTR reporter systems exhibit increased transactivation in the absence 
of SETDB1. A) Transient transfection of the CAT assay is broken down as follows: Lane 1 indicates the negative control; 
Lanes 2–4 titration of Tat from 0.01, 0.1 and 1.0 ug to establish a range of activation; Lanes 5–10 are in the presence of 0.1 ug 
Tat as well as the indicated transfected siRNAs. B) TZM-bl cells containing an integrated LTR-Luc were transfected with siGFP, 
siSETDB1, siTIF-1, siG9a, and siHP1 in addition to Tat (0.1 ug) to initiate transcription. Confirmation of the knockdown of 
SETDB1 is shown in a Western blot below. Each transfection and luciferase assay was repeated at least three times.Retrovirology 2008, 5:40 http://www.retrovirology.com/content/5/1/40
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[methyl-3H] methionine as a source of radio-labeled
methyl groups. Purified SETDB1 enzyme was incubated
with either no substrate, histone H3 N-terminal peptide
mutated at all 8 lysines (residues 2–37), four core histones
or WT Tat protein as a control as well as Tat mutant pep-
tides: K50A, K51A, and K5051A. The reaction mixtures
were incubated overnight at 37°C, spotted on GF/C filters
and washed to remove any free radioactivity. The filters
were then added to scintillation vials and counts were
taken. Figure 3A summarizes the results of the controls,
confirming that the enzyme was active when using full
length Tat or core histones with multiple lysine residues.
Both "no substrate" and Histone H3 mutant peptide
showed very minimal background counts. Interestingly
the level of Tat methylation using SETDB1 enzyme in vitro
was far more efficient as compared to the 4 core histones
that normally contained more than 20 lysine residues in
both the N-terminus and the core domains of histones.
Next, we utilized wild type and Tat peptide mutants to fur-
ther define the residues that are methylated in Tat. Figure
3B summarizes the experimental results for each of the Tat
peptide mutants. Overall we observed a two fold drop in
activity when using a K50A mutant, whereas there was
more than a 10 fold drop when using the K51A mutant
peptide. Double mutant peptide at lysines 50 and 51
showed no methylation activity. Collectively, these results
imply that both Tat lysine 50 and 51 are methylated, how-
ever lysine 51 is much more efficiently methylated when
using SETDB1 as the enzyme. Finally, it is important to
note that we have not been able to conclusively determine
whether lysine 51 is either mono- di- or tri- methylated
(although we have observed tri-methylation of Tat in IP
experiments, data not shown) hence a possible reason for
the better labeling of lysine 51 results seen in vitro.
We next asked whether methylation of Tat alters the spe-
cificity of cyclin T/TAR RNA binding in vitro. To do that,
we used a biotin TAR pull-down RNA experiment and
asked whether wild type or methylated Tat could still
bring down cyclin T. Our initial set of experiments
In vitro methyltransferase assays with SETDB1 reveal preferential methylation of Tat lysine 51 and loss binding to cyclin T Figure 3
In vitro methyltransferase assays with SETDB1 reveal preferential methylation of Tat lysine 51 and loss binding to cyclin T. A) The panel 
contains the negative and positive controls for the methylation assay. Both "no substrate" and histone H3 N-terminal mutant (K to A at positions 4, 9, 14, 
18, 23, 27, 36, and 37) serve as negative controls. Wild type Tat 1–86 protein was used for in vitro methylation assay. B) The panel shows the incorporation 
of methyl-3H onto the Tat mutant peptides. Tat K50A showed a ~2 fold drop in counts, whereas the K51A showed more than ~10 fold drop in activity. C) 
Purified biotin labeled TAR RNA or PolyU RNA was mixed with purified proteins including wild type Tat 1–86, Tat 101, methylated Tat 101, purified Cdk9/
cyclin T (data not shown) or extract. Unmodified and methylated Tat (1–86 and 1–101) were incubated with CEM nuclear extract containing endogenous 
Cdk9/cyclin T complexes (both active and inactive small and large complexes). Biotin-TAR RNA was added to the reaction mixture at the same time, proc-
essed and western blotted for presence of cyclin T.Retrovirology 2008, 5:40 http://www.retrovirology.com/content/5/1/40
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showed that when the reaction mixture contained TAR
RNA (but not Poly-U RNA), wild type Tat, and purified
Cdk9/cyclin T complex the affinity of cyclin T to TAR was
fairly stable (data not shown). Next, we incubated puri-
fied methylated Tat 101 protein with TAR RNA and extract
from CEM T-cells that contained endogenous Cdk9/cyclin
T complexes. Following incubation and pull-down of TAR
associated complexes, samples were separated on a 4–
20% gel and Western blotted for the presence of cyclin T.
Results, in Figure 3C showed that both unmodified Tat 86
or Tat 101 were able to bind to TAR RNA (lanes 1 and 2).
However, methylated Tat was unable to form a Tat/cyclin
T/TAR ternary complex in vitro (lane 3). Collectively, these
results indicate that Tat methylation may decrease the
affinity of Cdk9/cyclin T to the TAR RNA molecule.
Effect of siSETDB1 on HIV-1 reactivation
We finally asked if suppression of SETDB1 could indeed
activate a latent virus. For this purpose we transfected
HLM-1 cells with two siRNAs, siSETDB1 and siHP1. HLM-
1 cells are Hela T4 cells that contain one copy of mutated
virus in the Tat region (triple termination codon). These
cells could be used to activate virus with Tat or various
other stimuli including TNF. We therefore used siSETDB1
and siHP1 to first transfect HLM-1 cells and incubated
samples at 37°C for 48 hrs. We then removed cells from
the plate and incubated them with Tat protein for 4 hrs at
37°C. Subsequently, cells were plated again in complete
media. Tat has the ability to go through the cellular mem-
brane and activate HIV-1 LTR when incubated with cells.
Samples were carried out for 6 days and supernatants were
processed for RT activity. As seen in Figure 4A, addition of
no Tat showed no RT activity (Lane 1) however, Tat pro-
tein was able to activate the virus after 6 days (Lane 2). The
efficiency of viral production is usually low with the addi-
tion of just Tat to the cells in the absence of any other
manipulations. Cells treated with siSETDB1 (Lane 3) and
siHP1 (Lane 4) showed activation of the virus, but not
siCDK2 scramble (Lane 5). The levels of SETDB1 and HP1
were reduced in these transfected cells as judged by the
Western blot in Panel B. Collectively, these results further
imply that SETDB1 suppression is mediating a better acti-
vated transcription and viral progeny formation.
Discussion
We have previously shown that acetylation of Tat lysine
residues 50 and 51 results in an increase in transactivation
of the LTR and promotes the incorporation of the Cdk9/
cyclin T complex as well as other transcription factors into
the active complex [52]. As acetylation serves as an activa-
Effect of siSETDB1 on HIV-1 progeny formation Figure 4
Effect of siSETDB1 on HIV-1 progeny formation. Log phase HLM-1 cells were electroporated with siSETDB1 and siHP1 
for 48 hrs. Cells were subsequently removed and incubated with Tat for 4 hrs at 37°C in RPMI without serum. Cells were then 
plated in complete media for 6 days at 37°C and supernatants were process for RT activity. A) The effect of purified Tat pro-
tein on HLM-1 activation (lane 2) and subsequent super-activation with siSETDB1 and Tat protein in HLM-1 cells (lane 3). Lane 
4 was with siHP1 and lane 5 with siCDK scrambled RNA. B) Western blot of transfected cells for SETDB1, HP1 and actin. Cell 
extracts were processed post siRNA transfection and western blotted for various proteins. For the actin westerns, Lane 1 is 
from siSETDB1 treatment and lane 2 is from siHP1 treatment.Retrovirology 2008, 5:40 http://www.retrovirology.com/content/5/1/40
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tion signal for Tat, it is safe to suggest that there is also a
counter regulatory repression signal [63,64]. Indeed, very
recently Boulanger et al. and Xie et al. have shown that the
methylation of Tat arginine residues 52 and 53 result in a
decrease in association with viral transcription factors, as
well as compromised transcriptional activation of the LTR
[54,60]. Here we propose that the methylation of Tat
lysine 50 and 51 can result in a decrease in viral transcrip-
tion.
The post-translational modifications observed on the his-
tone tails can be easily correlated to modifications
observed on other proteins. Commonly seen trends of
modifications arise such as acetylation as a marker for
activation (i.e. the transition from heterochromatin to
euchromatin to initiate transcription) and methylation as
a marker for repression (i.e. the addition of methyl groups
to DNA to silence gene expression). Interestingly, the
amino acid residues that can usually accept a post-transla-
tional modification are less frequent throughout a pro-
tein, but are also usually involved in key interactions,
whether it can maintain the tertiary structure, enzymatic
active sites, or binding sites for protein-protein interac-
tions.
We show here that the lysine residues of Tat which are
prone to acetylation, 50 and 51, can be preferentially
methylated  in vitro by the histone methyltransferase
SETDB1. We show that the knockdown of this enzyme
causes an increase in the transactivation of the viral LTR.
The siRNA transfection experiments also included siRNAs
against TIF1, G9a, and HP1. SETDB1 as a histone methyl-
transferase trimethylates H3K9, therefore initiating the
formation of heterochromatin and gene silencing [65].
This H3K9 methylation also serves as a mark for recruit-
ment of the HP1 family of heterochromatin proteins [66].
Therefore, it is possible that the methylation of Tat by
SETDB1 could recruit HP1 and initiate transcriptional
silencing through chromatin remodeling.
We have previously shown that Tat binds to a number of
critical proteins including pCAF, Cyclin T1, and TIF-1
[31]. TIF-1α is a member of the TRIM (tripartite motif)
family of proteins. TRIM proteins contain the TRIM
domain which is composed of three zinc-binding
domains, a RING, a B-box type 1, and a B-box type 2, fol-
lowed by a coiled-coil region. The TRIM domain mediates
protein-protein interactions [67] and oligomerization
[68]. TIF-1α has been demonstrated to be a repressor of
RXR nuclear hormone receptors [69]. TIF-1 (TRIM24)
exhibits sequence similarities with the HIV restriction fac-
tor, TRIM5α, including the TRIM domain. It would be
intriguing to find out if TIF-1 controls similar pathways as
TRIM5α and could be a possible restriction factor for HIV-
1 gene expression or control of methylation of nucleic
acids. Possible reasoning for this is that TIF-1α has been
shown to bind to HP1α, HP1β, TFIIE, Hsp70, PML,
TAFII55, Zinc finger protein 10, RAR alpha, TAFII28, THR
alpha 1, and other TIF-1 subunits.
siRNA mediated knock-down of various HMTs, including
TIF-1 and SETDB1, indicated that decreased methyltrans-
ferase activity increased HIV LTR transcription in transient
transfection assays. We also showed that the methylation
of Tat by SETDB1 is preferential for both lysines 50 and
51. It is possible that any of these proteins is being mono-
, di-, or tri- methylated by SETDB1 at any given time "on"
or "off" of the HIV-1 LTR. Therefore, future experiments
will determine the rate and type of Tat methylation on the
LTR and in the presence of TAR RNA.
Although we have shown that the lysine 51 of HIV-1 Tat
can be methylated by SETDB1, it is unlikely that this mod-
ification alone completely shuts down the promoter activ-
ity. We propose that the interaction of SETDB1 with Tat
methylates the protein and that may be responsible for
the recruitment of part of the transcriptional repression
machinery to the HIV-1 genome. Figure 5 depicts our cur-
rent model for the initiation, elongation, and repression
of the promoter in relation to Tat modifications. The first
scenario predicts that unmodified Tat initiates transcrip-
tion by binding to TAR and recruiting the pTEFb into the
active complex. This leads to the acetylation of Tat by
CBP/p300. The second scenario promotes the elongation
of transcription by complexing with various other tran-
scription factors including remodeling complexes such as
SWI/SNF and p/CAF. The third and last step proposes that
Tat is methylated by SETDB1 and the enzyme recruits
DNA methyltransferase 3A (DNMT3A) and HDAC to the
elongation complex (possibly toward the 3' end of the
HIV-1 genome) to repress transcription and promote het-
erochromatin formation. SETDB1 has previously been
shown to directly interact with DNMT3A to promote gene
silencing [70] and it has also been shown to interact with
HDAC [71] which promotes the deacetylation of histones
and formation of heterochromatin. The recruitment of
these gene silencing proteins to the HIV-1 genome by the
methylation of Tat may be a strong indication for a possi-
ble transcriptional repression of the LTR. Future experi-
ments using ChIP assays will determine if such complexes
do indeed exist as the 3' end of the HIV-1 genome after
active transcription has occurred and prior to mRNA
translation, packaging, and release of the virus.
Materials and methods
SiRNA and protein Reagents
Control and SETDB1, HP1-γ, TIF-1α, and G9a double
stranded RNA oligonucleotides (siRNA) were purchased
from Dharmacon Research (Lafayette, CO). Human
SETDB1 and human SETDB2 proteins were expressed inRetrovirology 2008, 5:40 http://www.retrovirology.com/content/5/1/40
Page 9 of 13
(page number not for citation purposes)
baculovirus infected insect cells as amino-terminal fusion
proteins with poly-histidine (H6) or H6-maltose binding
protein (H6MBP). Baculovirus constructs were generated
by Gateway recombinational cloning of cDNA clone,
KG1T for SETDB1, (a generous gift from Dr. Greg Matera,
Case Western Reserve University) and I.M.A.G.E. clone
5266911 for SETDB2 (Open Biosystems). Proteins were
purified from soluble extracts by immobilized metal affin-
ity chromatography (IMAC) using a nickel charged His-
Trap-HP prepacked column (GE Healthcare) followed by
anionic exchange using a HiTrap Q prepacked column
(GE Healthcare) (H6MBP-SETDB1 only). Proteins were
stored in buffer containing 20 mM Tris-HCl pH8.0, 50
mM NaCl, 10% glycerol, and 1 mM dithiothreitol at -
80°C. Protein concentration was determined by Bradford
assay (BioRad) relative to BSA.
Core human histones (all four) were purified from Hela
cells and WT Tat 1–86 was overexpressed in an E. coli sys-
tem followed by column purification [72]. Anti-
ESET(SETDB1) and anti-SUV39H1 antibodies were pur-
chased from Cell Signaling (Danvers, MA). Anti-SETDB2
antibody was purchased from Abgent (San Diego, CA).
Anti-SETMAR and anti-G9a antibodies were purchased
from Abcam (Cambridge, MA). Tat WT and mutant pep-
tides were synthesized and purchased commercially from
SynBioSci (Livermore, CA) with the following sequences:
Tat WT 45–54 (I-S-Y-G-R-K-K-R-R-Q), Tat K50A (I-S-Y-G-
R-A-K-R-R-Q), Tat K51A (I-S-Y-G-R-K-A-R-R-Q), Tat K50,
51A (I-S-Y-G-R-A-A-R-R-Q). The purity of each peptide
was analyzed by HPLC to greater than 98%. Mass spectral
analysis was also performed to confirm the identity of
each peptide as compared to the theoretical mass
(Applied Biosystems Voyager System 1042). Peptides
were resuspended in dH2O to a concentration of 1 mg/
mL. Biotin-Tat and Biotin-Acetylated Tat were purified as
published previously [52].
Cell Culture
C8166 is an HTLV-1 infected T-cell line and TZM-bl is a
cell line derived from HeLa cells containing Tat-inducible
Luciferase and β-Gal reporter genes. C81 cells are grown in
RPMI-1640 media containing 10% FBS, 1% L-glutamine,
and 1% streptomycin/penicillin (Quality Biological).
TZM-bl cells were grown in Dulbecco's modified Eagle's
medium (DMEM) containing 10% FBS, 1% L-glutamine,
and 1% streptomycin/penicillin (Quality Biological). All
cells were incubated at 37°C and 5% CO2. Cells were cul-
tured to confluency and pelleted at 4°C for 15 min at
3,000 rpm. The cell pellets were washed twice with 25 mL
of phosphate buffered saline (PBS) with Ca2+ and Mg2+
(Quality Biological) and centrifuged once more. Cell pel-
lets were resuspended in lysis buffer (50 mM Tris-HCl, pH
7.5, 120 mM NaCl, 5 mM EDTA, 0.5% NP-40, 50 mM
NaF, 0.2 mM Na3VO4, 1 mM DTT, one complete protease
cocktail tablet/50 mL) and incubated on ice for 20 min,
with a gently vortexing every 5 min. Cell lysates were
transferred to eppendorf tubes and were centrifuged at
10,000 rpm for 10 min. Supernatants were transferred to
a fresh tube where protein concentrations were deter-
mined using Bio-Rad protein assay (Bio-Rad, Hercules,
CA).
The proposed model for the interaction of Tat with SETDB1 and chromatin remodelers in HIV-1 transcription Figure 5
The proposed model for the interaction of Tat with SETDB1 and chromatin remodelers in HIV-1 transcription. 
This model depicts the role of Tat in the involvement of activating transcription and chromatin remodeling. Tat is shown inter-
acting with Cdk9/cyclinT to bind to the TAR secondary structure element to initiate transcription. This binding complex 
recruits CBP/p300 which acetylates Tat, dissociates from the complex, and associates with SWI/SNF and p/CAF to facilitate 
transcriptional elongation. The repressive complex is shown with Tat being methylated by SETDB1, which may interact with 
DNA methyltransferase 3A and recruits HDAC to promote a compacted heterochromatin structure possibly at the 3' end of 
the HIV-1 genome.Retrovirology 2008, 5:40 http://www.retrovirology.com/content/5/1/40
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siRNA Transfection
SETDB1-directed siRNA pool (ON-TARGET plus SMART-
pool reagent L-020070-00), TIF-1α-directed siRNA pool
(ON-TARGET  plus SMARTpool reagent L-005387-00),
HP1-γ-directed siRNA pool (ON-TARGET plus SMART-
pool reagent L-010033-00) and G9a-directed siRNA pool
(ON-TARGET  plus SMARTpool reagent L-006937-00)
were purchased from Dharmacon. TZM-bl cells were
seeded in 6 well plates at 400,000 cells/well in DMEM
containing 10% FBS. The following day, the cells were
transfected with 0.01, 0.1, or 1.0 ug Tat plasmid and/or
with either siGFP, siSETDB1, siTIF-1, siG9a, or siHP1-γ
(Dharmacon) using Metafectene (Biontex) lipid reagent.
Total amount of siRNA was held constant using siGFP.
Cells were harvested forty-eight hours post transfection
for protein concentration and luciferase readings.
Biotin-Tat Pull-Down
Tat peptides (amino acids [aa] 42 to 52) were synthesized
with a biotin tag on a PAL-polyethylene glycol-polysty-
rene resin by continuous flow solid-phase synthesis on a
Perspective Biosystems Pioneer synthesizer (Framingham,
MA) using HBTU-activated 9-fluorenylmethoxy carboxyl
amino acids and were synthetically acetylated at positions
41/50/51 or 50/51, respectively [52]. Synthesized Tat pep-
tides (aa 36 to 53 and 42 to 54), labeled with biotin at the
N terminus and with or without an acetyl group at lysines
50 and 51, were used in the pull-down assays. C81 whole
cell extracts (2 mg) were prepared and incubated with
biotin labeled Tat peptides (WT and acetylated, 1.0 ug) in
TNE50 buffer (100 mM Tris-HCl, pH 7.5; 50 mM NaCl; 1
mM EDTA; 0.1% NP-40) overnight at 4°C. Streptavidin
beads (Boehringer Mannheim) were added to the mixture
and incubated for 2 h at 4°C. The beads were washed once
with each TNE300,  TNE150, and TNE50  + 0.1% NP-40.
Bound proteins were separated on 4–20% SDS-PAGE gel
and subjected to Western blotting with antibodies against
SUV39H1, SUV39H2, G9a, SETDB1, SETDB2, and SET-
MAR.
GST Pulldown
C81 whole cell extracts (2 mg) were prepared and incu-
bated with 10 ug of purified GST-Tat and GST-Tax con-
structs in TNE50 buffer (100 mM Tris-HCl, pH 7.5; 50 mM
NaCl; 1 mM EDTA; 0.1% NP-40) overnight at 4°C. The
following day, a 30% Protein A & G bead slurry (CalBio-
Chem, La Jolla, CA) was added to each reaction tube and
incubated for 2 hours at 4°C. Samples were spun and
washed twice with TNE300 + 0.1% NP-40 (100 mM Tris,
pH 8.0; 300 mM NaCl; 1 mM EDTA, 0.1% Nonidet P-40)
and 1× with TNE50 + 0.1% NP-40 to remove nonspecifi-
cally bound proteins. Samples were loaded and run on a
4–20% Tris-Glycine SDS-PAGE gel and subjected to West-
ern blotting with antibodies against ESET/SETDB1 and
SETDB2.
TAR RNA Streptavidin bead pull-down assay
Purified biotin labeled TAR RNA (N terminus, 3 ug) or
PolyU RNA were mixed with various purified proteins
including wild type Tat 1–86 (0.5 ug), Tat mutant K50/
51A (0.5 ug) or Baculovirus purified Cdk9/cyclin T (0.75
ug). Samples were incubated in TNE50 buffer (100 mM
Tris-HCl, pH 7.5; 50 mM NaCl; 1 mM EDTA; 0.1% NP-
40) with protease inhibitors and RNAsin overnight at
4°C. Streptavidin spharose beads (1/10 volume of a 30%
slurry; Boehringer Mannheim) were added to the mixture
and incubated for 2 h at 4°C. Bound proteins were sepa-
rated on 4 to 20% sodium dodecyl sulfate – polyacryla-
mide gel electrophoresis (SDS-PAGE), and subjected to
Western blotting with anti-cyclin T antibody.
GST-Tat 101 protein (2 mg) was first labeled in vitro with
purified SETDB1 and S-Adenosyl-L-[methyl-3H] methio-
nine. The reaction was incubated overnight at final vol-
ume of 35 ul. Also, 35 ul of sterile mineral oil was added
to top of reaction to avoid evaporation of the reaction dur-
ing the overnight incubation. The next day, 15 ul of 30%
Glutathion beads were added for 2 hrs at 4°C and
unbound material was washed with TNE50 + 0.1% NP-40.
GST-Tat protein was eluted for 4 hrs at 37°C with reduced
Glutathione. Purified methylated Tat was next incubated
with CEM nuclear extract containing endogenous Cdk9/
cyclin T complex (both active and inactive complex) at a
final 2 mg/reaction. Biotin-TAR RNA at 1.5 ug was also
added to the reaction mixture at the same time. Samples
were incubated in TNE50 buffer with protease inhibitors
and RNAsin overnight at 4°C. Subsequent reaction proce-
dures were similar to what was described above.
In vitro methyltransferase and Filter Binding Assay
Full length WT Tat (3 ug), Tat peptides (2 ug), Tat mutant
peptides (2 ug), histone H3 mutant peptide (2 ug, K to A
mutations at residues 4, 9, 14, 18, 23, 27, 36, and 37) and
core histones (1 ug) were incubated with 2 μg of purified
enzyme (SETDB1, SETDB2) in the presence of 0.55 μCi S-
Adenosyl-L-[methyl-3H] methionine (GE Healthcare, Pis-
cataway, NJ) and reaction buffer (50 mM Tris-HCl, pH
8.5, 20 mM KCl, 10 mM MgCl2, 250 mM sucrose, 10 μM
β-mercaptoethanol) overnight at 37°C in a final reaction
volume of 30 μl. The overnight methylation reactions
were spun briefly and spotted on GF/C membranes (Mil-
lipore) in duplicate and allowed to dry. The filters were
washed three times in excess cold 10% TCA, 1% sodium
phosphate followed by once with 100% ethanol. The fil-
ters were allowed to dry and counted in Beckman Coulter
LS6001C scintillation counter in scintillation fluid.
Transfection of HLM-1 cells
Log phase HLM-1 cells (5 × 106/sample) were electropo-
rated (210 volts, 800 mA) with siSETDB1 and siHP1 and
incubated in complete media for 48 hrs. Cells were subse-Retrovirology 2008, 5:40 http://www.retrovirology.com/content/5/1/40
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quently washed and treated with tyrpsin for 2 min. Next,
cells were washed and incubated with Tat (10 ug) in Tat
buffer (PBS + 0.01 mM DTT) for 4 hrs at 37°C in RPMI
without serum. Cells were then plated in complete media
for 6 days at 37°C and supernatants were process for RT
activity.
Luciferase Assay
Forty-eight hours post transfection, luciferase activity of
the firefly luciferase of the TZM-bl cells was measured
with the DualGlo Luciferase Assay (Promega). Lumines-
cence was read from a 96 well plate on an EG&G Berthold
luminometer. LTR driven firefly luciferase levels were nor-
malized to siGFP levels. Data shown represents at least
two repeats of each condition.
CAT Assay
Plasmids (LTR-CAT or CMV-Tat) were transfected by elec-
troporation using a Bio-Rad Gene Pulser (Bio-Rad, Rich-
mond, CA) at 960 μF and 230 Volts. After 48 h, cells were
lysed and chloramphenicol acetyltransferase (CAT) and
luciferase activities were determined. Luciferase was meas-
ured using the Luciferase assay system (Promega). For the
CAT assay, a standard reaction was performed by adding
the cofactor acetyl coenzyme A to a microcentrifuge tube
containing cell extract (50 ug) and radiolabeled (14C)
chloramphenicol in a final volume of 50 μl and incubat-
ing the mixture at 37°C for 1 h. The reaction mixture was
then extracted with ethyl acetate and separated by thin-
later chromatography on silica gel plates (Baker-flex silica
gel thin-later chromatography plates) in a chloroform-
methanol (19:1) solvent. The resolved reaction products
were then detected by exposing the plate to a Phos-
phorImager cassette.
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